Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 56
Filter
Add more filters










Publication year range
1.
Biochemistry ; 40(41): 12243-53, 2001 Oct 16.
Article in English | MEDLINE | ID: mdl-11591143

ABSTRACT

Overexpression of human apolipoprotein A-II (apo A-II) in mice induced postprandial hypertriglyceridemia and marked reduction in plasma HDL concentration and particle size [Boisfer et al. (1999) J. Biol. Chem. 274, 11564-11572]. We presently compared lipoprotein metabolism in three transgenic lines displaying plasma concentrations of human apo A-II ranging from normal to 4 times higher, under ad libitum feeding and after an overnight fast. Fasting dramatically decreased VLDL and lowered circulating human apo A-II in transgenic mice; conversely, plasma HDL levels increased in all genotypes. The apo A-I content of HDL was inversely related to the expression of human apo A-II, probably reflecting displacement of apo A-I by an excess of apo A-II. Thus, the molar ratios of apo A-II/A-I in HDL were significantly higher in fed as compared with fasted animals of the same transgenic line, while endogenous LCAT activity concomitantly decreased. The number and size of HDL particles decreased in direct proportion to the level of human apo A-II expression. Apo A-II was abundantly present in all HDL particles, in contrast to apo A-I mainly present in large ones. Two novel findings were the presence of pre-beta migrating HDL transporting only human apo A-II in the higher-expressing mice and the increase of plasma HDL concentrations by fasting in control and transgenic mice. These findings highlight the reciprocal modifications of VLDL and HDL induced by the feeding-fasting transition and the key role of the molar ratio of apo A-II/A-I as a determinant of HDL particle metabolism and pre-beta HDL formation.


Subject(s)
Apolipoprotein A-II/blood , Apolipoprotein A-I/blood , Lipoproteins, HDL/blood , Animals , Apolipoprotein A-II/genetics , Arteriosclerosis/blood , Arteriosclerosis/etiology , Eating , Fasting , Gene Expression , High-Density Lipoproteins, Pre-beta , Humans , Hyperlipoproteinemia Type IV/blood , Hyperlipoproteinemia Type IV/genetics , Lipoproteins, LDL/blood , Lipoproteins, VLDL/blood , Mice , Mice, Inbred C57BL , Mice, Inbred CBA , Mice, Transgenic , Particle Size
2.
Toxicol In Vitro ; 15(4-5): 373-8, 2001.
Article in English | MEDLINE | ID: mdl-11566566

ABSTRACT

The gastrointestinal tract represents the first barrier met by the exogenous compounds of food or orally delivered drugs. To be transferred to the whole body, drugs and xenobiotics have first to pass through the intestinal epithelium, where detoxification systems have to minimize the potential of damage from toxic xenobiotics. However, most studies on xenobiotic-metabolizing enzymes have focused on liver enzymes. Such a situation may be explained by the fact that this organ is the site of toxification/detoxification for both endogenous and exogenous compounds, and also because adequate in vitro hepatocytes models have been available for a long time. By contrast, normal cellular models for the in vitro study of the intestinal processes of biotransformation still remain difficult to obtain. In the present report we will thus focus on the most commonly used models, which are Caco-2 cells and their derivative clones, and we will report recent procedures that allow the isolation of normal enterocytes which maintain their functions and integrity for several hours or even several days. Their respective performance and advantages for the study of the induction of the drug-metabolizing enzymes will be discussed.


Subject(s)
Intestinal Mucosa/drug effects , Xenobiotics/toxicity , Animals , Caco-2 Cells , Cobalt/pharmacology , Cytochrome P-450 CYP1A1/antagonists & inhibitors , Cytochrome P-450 CYP1A1/genetics , Cytochrome P-450 CYP1A1/metabolism , Cytochrome P-450 CYP3A , Cytochrome P-450 Enzyme Inhibitors , Cytochrome P-450 Enzyme System/genetics , Cytochrome P-450 Enzyme System/metabolism , Enterocytes/cytology , Enterocytes/drug effects , Enterocytes/metabolism , Enzyme Induction , Enzyme Inhibitors/pharmacology , Humans , Inactivation, Metabolic , Intestinal Mucosa/cytology , Intestinal Mucosa/enzymology , Mixed Function Oxygenases/antagonists & inhibitors , Mixed Function Oxygenases/genetics , Mixed Function Oxygenases/metabolism , Models, Biological , RNA, Messenger/metabolism , Xenobiotics/metabolism , beta-Naphthoflavone/pharmacology
3.
J Neurochem ; 76(1): 117-27, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11145984

ABSTRACT

Although the genetic link between the epsilon 4 allele of apolipoprotein E (apoE) and Alzheimer's disease (AD) is well established, the apoE isoform-specific activity underlying this correlation remains unclear. We have recently characterized the interaction of the soluble the amyloid-beta peptide (A beta) with model membrane and demonstrated that non-fibrillar A beta peptide, including N-terminal truncated forms of A beta, induced apoptotic cell death in primary rat cortical neurones in vitro. To further investigate the potential interaction between apoE and A beta in the pathogenesis of AD, we have determined the effect of apoE isoforms on the neurotoxicity of non-fibrillar A beta peptides. We demonstrate here that the apoE2 and E3 isoforms protect cortical neurones against apoptotic cell death induced by a non-fibrillar form of the A beta(1-40), A beta(12-42), A beta(29-40) and A beta(29-42) peptides, whereas apoE4 had no effect. This effect involves the formation of stable complexes between apoE and the C-terminal domain (e.g. amino acids 29-40) of A beta(1-40). Interestingly, apoE had no effect on the toxicity induced by aggregated A beta peptides, suggesting a lack of interaction between apoE and amyloid fibrils. Our results provide evidence that interaction with the C-terminal domain of A beta, apoE2 and E3, but not apoE4, inhibits the interactions of the non-fibrillar A beta peptide with the plasma membrane of neurones, A beta peptide aggregation and subsequent neurotoxicity.


Subject(s)
Amyloid beta-Peptides/toxicity , Apolipoproteins E/metabolism , Cerebral Cortex/metabolism , Neurons/metabolism , Peptide Fragments/toxicity , Amino Acid Sequence , Amyloid beta-Peptides/chemical synthesis , Amyloid beta-Peptides/chemistry , Animals , Apolipoprotein E2 , Apolipoprotein E3 , Apolipoprotein E4 , Apolipoproteins E/pharmacology , Apoptosis/drug effects , Cell Membrane/metabolism , Cell Survival/drug effects , Cells, Cultured , Cerebral Cortex/cytology , Cerebral Cortex/drug effects , Neurons/cytology , Neurons/drug effects , Peptide Fragments/chemical synthesis , Peptide Fragments/chemistry , Protein Binding/drug effects , Protein Isoforms/metabolism , Protein Isoforms/pharmacology , Rats , Rats, Wistar
4.
J Neurochem ; 75(6): 2298-308, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11080181

ABSTRACT

Neuronal loss is a salient feature of prion diseases. However, its cause and mechanism, particularly its relationship with the accumulation and precipitation of the pathogenic, protease-resistant isoform PrP(Sc) of the cellular prion protein PrP(C), are still an enigma. Several studies suggest that neuronal loss could occur through a process of programmed cell death, which is consistent with the lack of inflammation in these conditions. By analogy with the pathological events occurring during the development of Alzheimer's disease, controversies still exist regarding the relationship between amyloidogenesis, prion aggregation, and neuronal loss. We recently demonstrated that a prion protein fragment (118-135) displayed membrane-destabilizing properties and was able to induce, in a nonfibrillar form, the fusion of unilamellar liposomes. To unravel the mechanism of prion protein neurotoxicity, we characterize the effects of the human Pr[118-135] peptide on rat cortical neurons. We demonstrate that low concentrations of the Pr[118-135] peptide, in a nonfibrillar form, induce a time- and dose- dependent apoptotic cell death, including caspase activation, DNA condensation, and fragmentation. This toxicity might involve oxidative stress, because antioxidant molecules, such as probucol and propyl gallate, protect neurons against prion peptide toxicity. By contrast, a nonfusogenic variant Pr[118-135, 0 degrees ] peptide, which displays the same amino acid composition but several amino acid permutations, is not toxic to cortical neurons, which emphasizes the critical role of the fusogenic properties of the prion peptide in its neurotoxicity. Taken together, our results suggest that the interaction between the Pr[118-135] peptide and the plasma membrane of neurons might represent an early event in a cascade leading to neurodegeneration.


Subject(s)
Apoptosis , Neurons/drug effects , Peptide Fragments/pharmacology , Prions/pharmacology , Amino Acid Chloromethyl Ketones/pharmacology , Amyloid beta-Peptides/analogs & derivatives , Amyloid beta-Peptides/pharmacology , Animals , Antioxidants/pharmacology , Caspase Inhibitors , Caspases/metabolism , Cell Nucleus/drug effects , Cell Nucleus/pathology , Cell Survival/drug effects , Cells, Cultured , Cerebral Cortex/drug effects , Cerebral Cortex/metabolism , Cerebral Cortex/pathology , DNA Fragmentation/drug effects , Dose-Response Relationship, Drug , Enzyme Inhibitors/pharmacology , L-Lactate Dehydrogenase/metabolism , Membrane Fusion/drug effects , Neurons/metabolism , Neurons/pathology , Peptide Fragments/metabolism , Rats , Rats, Wistar , Tetrazolium Salts , Thiazoles
5.
Int J Tissue React ; 22(2-3): 67-78, 2000.
Article in English | MEDLINE | ID: mdl-10937356

ABSTRACT

Our understanding of the in vivo metabolic functions of apoA-I and A-II has greatly advanced with the use of transgenic mice, but the physiological role of apoA-IV remains elusive. Both apoA-I and A-II are necessary for the structural stability of high-density lipoprotein (HDL). Structural differences exist between human and mouse A apoproteins because: i) human cholesterol ester transfer protein, lecithin cholesterol acyl transferase and phospholipid transfer protein interact better with human apoA-I; ii) human apoA-I and A-II, alone or in combination, form polydisperse instead of monodisperse HDL particles. Human apoA-II overexpression has highlighted its inhibitory effect on lipoprotein lipase and hepatic lipase, resulting in hypertriglyceridemia and concomitantly decreased HDL and apoA-I. After long-term challenge with an atherogenic diet, mice are less protected against lesion formation by human apoA-II, mouse apoA-II being overtly proatherogenic. On the other hand, human apoA-I confers great protection against lesion formation and causes reduction of preexisting lesions. Human apoA-IV is also protective, although the mechanisms by which this protection is achieved remain to be determined.


Subject(s)
Apolipoprotein A-II/biosynthesis , Apolipoprotein A-I/biosynthesis , Apolipoproteins A/biosynthesis , Cholesterol/metabolism , Animals , Apolipoprotein A-I/genetics , Apolipoprotein A-II/genetics , Apolipoprotein A-II/physiology , Apolipoproteins A/genetics , Arteriosclerosis , Biological Transport, Active , Disease Susceptibility , Gene Expression Profiling , Homeostasis , Humans , Lipoproteins, HDL/blood , Mice , Mice, Knockout , Mice, Transgenic
6.
Cell Mol Life Sci ; 57(5): 705-15, 2000 May.
Article in English | MEDLINE | ID: mdl-10892337

ABSTRACT

Despite an exponential production of data, Alzheimer's disease (AD) remains an enigma. Unresolved questions persist in the face of the heterogeneity of this neuropathology. Recent progress in understanding mechanisms for AD results from the study of amyloid precursor protein (APP) metabolism and the involvement of senile plaque-associated proteins. In addition to the amyloid cascade hypothesis, alternative schemes emerge, in which the amyloid peptide is not the primary effector of the disease. Perturbations of vesicular trafficking, the cytoskeletal network, and membrane cholesterol distribution could be central events. Furthermore, since the physiological role of APP, presenilins, and apolipoprotein E in the central nervous system are not completely understood, their involvement in AD etiology remains speculative. New actors have to be found to try to explain sporadic cases and non-elucidated familial cases.


Subject(s)
Alzheimer Disease/etiology , Alzheimer Disease/metabolism , Alzheimer Disease/pathology , Amyloid beta-Peptides/metabolism , Amyloid beta-Protein Precursor/metabolism , Apolipoproteins E/metabolism , Apoptosis , Cell Membrane/metabolism , Cholesterol/metabolism , Humans , Membrane Proteins/metabolism , Models, Biological , Necrosis , Neuroglia/pathology , Presenilin-1 , Presenilin-2 , tau Proteins/metabolism
7.
Curr Opin Lipidol ; 11(2): 149-53, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10787176

ABSTRACT

Our understanding of HDL metabolism in vivo has greatly advanced from studies with transgenic animals. Interactions between HDL apolipoproteins, transfer proteins, lipolytic enzymes and receptors modulate HDL size, particle number and fractional catabolic rate. The protective effect of HDL on atherosclerosis depends on the combined actions of HDL proteins and the metabolism of apo B-lipoproteins.


Subject(s)
Lipoproteins, HDL/genetics , Mice, Transgenic/metabolism , Animals , Apolipoprotein A-I/metabolism , Apolipoprotein A-II/metabolism , Humans , Kinetics , Lipase/metabolism , Lipoprotein Lipase/metabolism , Lipoproteins, HDL/physiology , Liver/enzymology , Mice , Mice, Transgenic/genetics
8.
J Neurochem ; 73(4): 1626-34, 1999 Oct.
Article in English | MEDLINE | ID: mdl-10501209

ABSTRACT

The toxicity of the nonaggregated amyloid beta-peptide (1-40) [A beta(1-40)] on the viability of rat cortical neurons in primary culture was investigated. We demonstrated that low concentrations of A beta peptide, in a nonfibrillar form, induced a time- and dose-dependent apoptotic cell death, including DNA condensation and fragmentation. We compared the neurotoxicity of the A beta(1-40) peptide with those of several A beta-peptide domains, comprising the membrane-destabilizing C-terminal domain of A beta peptide (e.g., amino acids 29-40 and 29-42). These peptides reproduced the effects of the (1-40) peptide, whereas mutant nonfusogenic A beta peptides and the central region of the A beta peptide (e.g., amino acids 13-28) had no effect on cell viability. We further demonstrated that the neurotoxicity of the nonaggregated A beta peptide paralleled a rapid and stable interaction between the A beta peptide and the plasma membrane of neurons, preceding apoptosis and DNA fragmentation. By contrast, the peptide in a fibrillar form induced a rapid and dramatic neuronal death mainly through a necrotic pathway, under our conditions. Taken together, our results suggest that A beta induces neuronal cell death by either apoptosis and necrosis and that an interaction between the nonfibrillar C-terminal domain of the A beta peptide and the plasma membrane of cortical neurons might represent an early event in a cascade leading to neurodegeneration.


Subject(s)
Amyloid beta-Peptides/chemistry , Amyloid beta-Peptides/toxicity , Apoptosis/drug effects , Cell Nucleus/ultrastructure , Neurons/drug effects , Peptide Fragments/chemistry , Peptide Fragments/toxicity , Amino Acid Sequence , Amyloid beta-Peptides/chemical synthesis , Animals , Cell Membrane/drug effects , Cell Membrane/ultrastructure , Cell Nucleus/drug effects , Cell Survival/drug effects , Cells, Cultured , Cerebral Cortex/cytology , Embryo, Mammalian , Molecular Sequence Data , Neurons/cytology , Neurons/physiology , Peptide Fragments/chemical synthesis , Rats , Rats, Wistar , Structure-Activity Relationship
9.
J Neurochem ; 73(2): 742-9, 1999 Aug.
Article in English | MEDLINE | ID: mdl-10428072

ABSTRACT

A growing amount of evidence indicates the involvement of extracellular matrix components, especially laminins, in the development of Alzheimer's disease, although their role remains unclear. In this study, we clearly demonstrate that laminin 1 inhibits beta-amyloid peptide (Abeta)-induced neuronal cell death by preventing the fibril formation and interaction of the Abeta peptide with cell membranes. The presence of laminin at a laminin/Abeta peptide molar ratio of 1:800 significantly inhibits the Abeta-induced apoptotic events, together with inhibition of amyloid fibril formation. The inhibitory effects of laminin 1 were time- and dose-dependent, whereas laminin 2 had less effect on Abeta neurotoxicity. A preincubation of laminin and Abeta was not required to observe the protective effect of laminin, suggesting a direct interaction between laminin 1 and Abeta. Moreover, laminin had no effect on the toxicity of the fibrillar Abeta peptide, suggesting an interaction of laminin with nonfibrillar species of the Abeta peptide, sequestering the peptide in a soluble form. These data extend our understanding of laminin-dependent binding of Abeta and highlight the possible modulation role of laminin regarding Abeta aggregation and neurotoxicity in vivo.


Subject(s)
Amyloid beta-Peptides/toxicity , Laminin/pharmacology , Neurons/cytology , Neurons/drug effects , Peptide Fragments/toxicity , Alzheimer Disease/metabolism , Animals , Cell Membrane/drug effects , Cell Membrane/metabolism , Cell Survival/drug effects , Cells, Cultured , Cerebral Cortex/cytology , Fetus/cytology , L-Lactate Dehydrogenase/metabolism , Nerve Degeneration/drug therapy , Nerve Degeneration/metabolism , Neurofibrillary Tangles/metabolism , Neurons/enzymology , Neuroprotective Agents/pharmacology , Rats , Rats, Wistar , Solubility
10.
J Biol Chem ; 274(17): 11564-72, 1999 Apr 23.
Article in English | MEDLINE | ID: mdl-10206963

ABSTRACT

Two lines of transgenic mice, hAIItg-delta and hAIItg-lambda, expressing human apolipoprotein (apo)A-II at 2 and 4 times the normal concentration, respectively, displayed on standard chow postprandial chylomicronemia, large quantities of very low density lipoprotein (VLDL) and low density lipoprotein (LDL) but greatly reduced high density lipoprotein (HDL). Hypertriglyceridemia may result from increased VLDL production, decreased VLDL catabolism, or both. Post-Triton VLDL production was comparable in transgenic and control mice. Postheparin lipoprotein lipase (LPL) and hepatic lipase activities decreased at most by 30% in transgenic mice, whereas adipose tissue and muscle LPL activities were unaffected, indicating normal LPL synthesis. However, VLDL-triglyceride hydrolysis by exogenous LPL was considerably slower in transgenic compared with control mice, with the apparent Vmax of the reaction decreasing proportionately to human apoA-II expression. Human apoA-II was present in appreciable amounts in the VLDL of transgenic mice, which also carried apoC-II. The addition of purified apoA-II in postheparin plasma from control mice induced a dose-dependent decrease in LPL and hepatic lipase activities. In conclusion, overexpression of human apoA-II in transgenic mice induced the proatherogenic lipoprotein profile of low plasma HDL and postprandial hypertriglyceridemia because of decreased VLDL catabolism by LPL.


Subject(s)
Apolipoprotein A-II/genetics , Hypertriglyceridemia/genetics , Lipoproteins, VLDL/blood , Animals , Apolipoprotein A-II/blood , Female , Humans , Hypertriglyceridemia/blood , Lipoprotein Lipase/blood , Lipoproteins, HDL/blood , Liver/enzymology , Mice , Mice, Inbred C57BL , Mice, Inbred CBA , Mice, Transgenic , Protein Isoforms/blood , Protein Isoforms/genetics
11.
Exp Cell Res ; 247(2): 373-9, 1999 Mar 15.
Article in English | MEDLINE | ID: mdl-10066365

ABSTRACT

Transcriptional activity of the human apolipoprotein (apo) A-II promoter has been reported in transiently transfected Caco-2 cells, but not in the intestine in vivo. In the present study we established that the transcription of a stably transfected reporter gene under the control of the -911/+29 human apo A-II, decreases with the onset of the differentiation process. This decrease paralleled that of the expression of the endogenous apo A-II gene. The decrease in apo A-II expression is also followed by a marked increase in the expression of the intestine-specific apo A-IV gene, analyzed here as a marker of enterocytic differentiation. Using clonal glucose metabolic variants of Caco-2 cells we have also observed that the lowest levels of apo A-II mRNA are associated with the lowest rates of glucose consumption. The illegitimate apo A-II transcriptional activity observed in Caco-2 cells is linked to the presence of DNase-I hypersensitive sites within the enhancer. This reflects a chromatin organization which allows, in Caco-2 cells as in the liver, the communication between the apo A-II enhancer and the proximal promoter, unlike what is observed in intestinal epithelial cells.


Subject(s)
Apolipoprotein A-II/genetics , Chromatin , Gene Expression Regulation , Caco-2 Cells , Deoxyribonuclease I , Humans , Transcription, Genetic
12.
Nucleic Acids Res ; 27(4): 1104-17, 1999 Feb 15.
Article in English | MEDLINE | ID: mdl-9927745

ABSTRACT

DNase I footprinting of the apoA-II promoter using sterol regulatory element binding protein-2 [(SREBP-2 (1-458)] expressed in bacteria identified four protected regions, designated AIIAB (-64 to -48), AIICD (-178 to -154), AIIDE (-352 to -332) and AIIK (-760 to -743), which bind SREBP-2 and contain either palindromic or direct repeat motifs. Potassium permanganate and dimethyl sulfate interference experiments using the AIIAB region as probe showed that the nucleotides of a decameric palindromic repeat RTCAMVTGMY and two 5' T residues participate in DNA-protein interactions. SREBP-2 transactivated the intact (-911/+29) apoA-II promoter 1.7-fold and truncated apoA-II promoter segments which contain one, two or three SREBP-2 sites 11- to 17-fold in HepG2 cells. Transactivation of a promoter construct containing the binding site AIIAB and the apoA-II enhancer, which includes the binding site AIIK, was abolished by mutations in element AIIAB. An SREBP-2 mutant defective in DNA binding caused a dose-dependent repression of the apoA-II promoter activity. Repression was also caused by an SREBP-2 mutant which lacks the N-terminal activation domain (residues 1-93) but binds normally to its cognate sites. In contrast, a double SREBP-2 mutant which lacks both the DNA binding and the activation domains has no effect on the apoA-II promoter activity. Overall, the findings suggest that SREBP-2 can transactivate the apoA-II promoter by binding to multiple sites. Furthermore, the repression caused by the DNA binding deficient mutants results from squelching of positive activator(s) which appear to recognize the activation domain of SREBP-2.


Subject(s)
Apolipoprotein A-II/genetics , DNA-Binding Proteins/metabolism , Promoter Regions, Genetic , Transcription Factors/metabolism , Transcriptional Activation , Animals , Base Sequence , Binding Sites , DNA, Complementary , DNA-Binding Proteins/genetics , Gene Expression Regulation , Humans , Molecular Sequence Data , Sterol Regulatory Element Binding Protein 2 , Transcription Factors/genetics , Tumor Cells, Cultured
13.
J Biol Chem ; 274(8): 4954-61, 1999 Feb 19.
Article in English | MEDLINE | ID: mdl-9988739

ABSTRACT

Spatial gene expression in the intestine is mediated by specific regulatory sequences. The three genes of the apoA-I/C-III/A-IV cluster are expressed in the intestine following cephalocaudal and crypt-to-villus axes. Previous studies have shown that the -780/-520 enhancer region of the apoC-III gene directs the expression of the apoA-I gene in both small intestinal villi and crypts, implying that other unidentified elements are necessary for a normal intestinal pattern of apoA-I gene expression. In this study, we have characterized transgenic mice expressing the chloramphenicol acetyltransferase gene under the control of different regions of the apoC-III and apoA-IV promoters. We found that the -890/+24 apoC-III promoter directed the expression of the reporter gene in crypts and villi and did not follow a cephalocaudal gradient of expression. In contrast, the -700/+10 apoA-IV promoter linked to the -500/-890 apoC-III enhancer directed the expression of the reporter gene in enterocytes with a pattern of expression similar to that of the endogenous apoA-IV gene. Furthermore, linkage of the -700/-310 apoA-IV distal promoter region to the -890/+24 apoC-III promoter was sufficient to restore the appropriate pattern of intestinal expression of the reporter gene. These findings demonstrate that the -700/-310 distal region of the apoA-IV promoter contains regulatory elements that, in combination with proximal promoter elements and the -500/-890 enhancer, are necessary and sufficient to restrict apoC-III and apoA-IV gene expression to villus enterocytes of the small intestine along the cephalocaudal axis.


Subject(s)
Apolipoproteins A/genetics , Apolipoproteins C/genetics , Enhancer Elements, Genetic , Gene Expression Regulation , Animals , Apolipoprotein C-III , Chloramphenicol O-Acetyltransferase/genetics , Intestine, Small/metabolism , Mice , Mice, Transgenic , RNA, Messenger/genetics , Regulatory Sequences, Nucleic Acid
14.
J Neurochem ; 72(1): 230-7, 1999 Jan.
Article in English | MEDLINE | ID: mdl-9886074

ABSTRACT

Growing evidence indicates the involvement of apolipoprotein E (apoE) in the development of late-onset and sporadic forms of Alzheimer's disease, although its exact role remains unclear. We previously demonstrated that beta-amyloid peptide (Abeta) displays membrane-destabilizing properties and that only apoE2 and E3 isoforms inhibit these properties. In this study, we clearly demonstrate that the carboxy-terminal lipid-binding domain of apoE (e.g., residues 200-299) is responsible for the Abeta-binding activity of apoE and that this interaction involves pairs of apoE amphipathic alpha-helices. We further demonstrate that Abeta is able to inhibit the association of the C-terminal domain of apoE with lipids due to the formation of Abeta/apoE complexes resistant to sodium dodecyl sulfate-polyacrylamide gel electrophoresis. On the contrary, the amino-terminal receptor-binding domain of apoE (e.g., residues 129-169) is not able to form stable complexes with Abeta. These data extend our understanding of human apoE-dependent binding of Abeta by involving the C-terminal domain of apoE in the efficient formation of apoE/Abeta complex.


Subject(s)
Alzheimer Disease/metabolism , Amyloid beta-Peptides/metabolism , Apolipoproteins E/metabolism , Apolipoprotein E2 , Apolipoprotein E3 , Apolipoproteins E/chemistry , Binding Sites/physiology , Humans , Lipid Metabolism , Liposomes/metabolism , Membrane Fusion/physiology , Peptide Fragments/metabolism , Protein Structure, Secondary , Protein Structure, Tertiary
15.
J Biol Chem ; 274(3): 1216-25, 1999 Jan 15.
Article in English | MEDLINE | ID: mdl-9880489

ABSTRACT

The activity of the human apoA-II promoter is controlled by a synergistic interaction of the distal enhancer and the proximal promoter. An important role in apoA-II promoter activity is exerted by a transcription factor, designated CIIIB1, which binds to the proximal element AB and the distal elements of the enhancer, K and L. In the present communication we establish that CIIIB1 corresponds to the previously described factor, upstream stimulatory factor (USF) using the following criteria. (a) Purification of CIIIB1 by affinity chromatography provided a heat-stable protein with an apparent molecular mass of 45 kDa that cross-reacted with anti-USF1 and -USF2a antibodies; (b) CIIIB1 bound to the elements AB, K, and L was supershifted by these antibodies; (c) the heterodimer USF1/2a is the predominant form that corresponds to CIIIB1. Cotransfection experiments in HepG2 cells established the functional significance of USF in apoA-II transcription. It was found that the minimal promoter AB was transactivated by USF2a. In addition, all three E-box motifs present in elements AB, K and L are necessary for maximum transactivation by USF2a. A dominant negative form of USF2a inhibits the activity of apoA-II promoter. The USF1/2a heterodimer, which is naturally expressed in the liver, is as efficient as the USF2a homodimer in the transactivation of apoA-II promoter/enhancer constructs. Cotransfection experiments in COS-1 cells showed that hepatic nuclear factor 4 (HNF-4) synergized with USF2a in the transactivation of the apoA-II promoter. In addition, we showed that HNF-4 and USF2a bind to the enhancer cooperatively. This may account for the transcriptional synergism observed between USF and HNF-4 in the transactivation of the apoA-II promoter.


Subject(s)
Apolipoprotein A-II/genetics , DNA-Binding Proteins , Helix-Loop-Helix Motifs , Phosphoproteins/metabolism , Transcription Factors/metabolism , Transcription, Genetic , Animals , Base Sequence , Basic Helix-Loop-Helix Leucine Zipper Transcription Factors , COS Cells , Cell Line , Chromatography, Affinity , DNA/metabolism , Hepatocyte Nuclear Factor 4 , Humans , Molecular Sequence Data , Nuclear Proteins/metabolism , Promoter Regions, Genetic , Rats , Transcriptional Activation , Upstream Stimulatory Factors
16.
Atherosclerosis ; 139(2): 351-62, 1998 Aug.
Article in English | MEDLINE | ID: mdl-9712342

ABSTRACT

The displacement of apolipoprotein (apo) A-I by apo A-II is a major event in the remodeling of high density lipoproteins (HDL). In the present study, we investigated the displacement of apo A-I both from native and reconstituted HDL (rHDL) by either apo A-II or by the C-terminal helical peptide (i.e. residues 53-70). We studied the remodeling process of the original particles, the changes in size and composition and in their lecithin:cholesterol acyltransferase (LCAT) activating properties. Using gel filtration, we show that, at low apo A-II/AI ratios, the initial lipid apolipoprotein complex containing 2 mol apo A-I is remodeled into a mixed complex containing apo A-I and apo A-II, involving the displacement of one apo A-I by apo A-II. Upon addition of a larger amount of apo A-II, the rHDL particles become more heterogeneous and of larger size. Immunoblotting of the particles separated by non denaturing gradient gel electrophoresis shows that most of the apo A-I remains associated with the largest particles. The LCAT activation properties of the remodeled complexes decrease upon addition of either apo A-II or its C-terminal helix. This decrease is more pronounced when rHDL are incubated with the apo A-II C-terminal helix than with native apo A-II, as VmaX decreases from 28 to 16 and 7 nmol cholesteryl ester/ml per h respectively, whereas Km remains unchanged. The displacement of apo A-I observed with rHDL also occurred with native HDL particles as demonstrated by two-dimensional gel electrophoresis, using pyrene-phospholipid labeled HDL. Displacement of apo A-I generates pre-beta1 migrating particles containing apo A-I and phospholipids. We therefore propose that apo A-II has a dual effect on the role of HDL in reverse cholesterol transport: displacement of apo A-I from rHDL results in a negative control of the LCAT activity, while generation of pre-beta1 migrating particles enhances the formation of potential acceptors of cellular cholesterol.


Subject(s)
Apolipoprotein A-II/chemistry , Apolipoprotein A-II/metabolism , Apolipoprotein A-I/metabolism , Lipoproteins, HDL/metabolism , Phosphatidylcholine-Sterol O-Acyltransferase/metabolism , Binding, Competitive/physiology , Electrophoresis, Gel, Two-Dimensional , Electrophoresis, Polyacrylamide Gel , Enzyme Activation/physiology , Humans , Immunoblotting , Microscopy, Electron
17.
Eur J Biochem ; 253(1): 328-38, 1998 Apr 01.
Article in English | MEDLINE | ID: mdl-9578492

ABSTRACT

To assess the functional properties of apolipoprotein (apo) AII and to investigate the mechanism leading to the displacement of apo AI from native and reconstituted high-density lipoproteins (HDL and r-HDL) by apo AII, wild-type and variant apo AII peptides were synthesized. The wild-type peptides, residues 53-70 and 58-70, correspond to the C-terminal helix of apo AII and are predicted to insert at a tilted angle into a lipid bilayer. We demonstrate that both the apo AII-(53-70) peptide, and to a lesser extent the apo AII-(58-70) peptide are able to induce fusion of unilamellar lipid vesicles together with membrane leakage, and to displace apo AI from HDL and r-HDL. Two variants of the apo AII-(53-70)-wild-type (WT) peptide, designed either to be parallel to the water/lipid interface [apo AII-(53-70)-0 degrees] or to retain an oblique orientation [apo AII-(53-70)-30 degrees], were synthesized in order to test the influence of the obliquity on their fusogenic properties and ability to displace apo AI from HDL. The parallel variant did not bind lipids, due to its self-association properties. However, the apo AII-(53-70)-30 degrees variant was fusogenic and promoted the displacement of apo AI from HDL. Moreover, the extent of fusion of the apo AII-(53-70)-WT, apo AII-(58-70)-WT and apo AII-(53-70)-30 degrees peptides was related to the alpha-helical content of the lipid-bound peptides measured by infrared spectroscopy. Infrared measurements using polarized light also confirmed the oblique orientation of the helical component of the three peptides. In native and r-HDL, the tilted insertion of the C-terminal helix of apo AII resulting in a partial destabilization of the HDL external lipid layer might contribute to the displacement of apo AI by apo AII.


Subject(s)
Apolipoprotein A-II/metabolism , Apolipoprotein A-II/pharmacology , Apolipoprotein A-I/metabolism , Lipoproteins, HDL/metabolism , Membrane Fusion/drug effects , Amino Acid Sequence , Apolipoprotein A-II/chemistry , Humans , In Vitro Techniques , Liposomes , Models, Molecular , Molecular Sequence Data , Peptide Fragments/chemistry , Peptide Fragments/metabolism , Peptide Fragments/pharmacology , Protein Conformation , Protein Structure, Secondary
18.
Nature ; 392(6674): 398-401, 1998 Mar 26.
Article in English | MEDLINE | ID: mdl-9537324

ABSTRACT

The adipocyte-specific hormone leptin, the product of the obese (ob) gene, regulates adipose-tissue mass through hypothalamic effects on satiety and energy expenditure. Leptin acts through the leptin receptor, a single-transmembrane-domain receptor of the cytokine-receptor family. In rodents, homozygous mutations in genes encoding leptin or the leptin receptor cause early-onset morbid obesity, hyperphagia and reduced energy expenditure. These rodents also show hypercortisolaemia, alterations in glucose homeostasis, dyslipidaemia, and infertility due to hypogonadotropic hypogonadisms. In humans, leptin deficiency due to a mutation in the leptin gene is associated with early-onset obesity. Here we describe a homozygous mutation in the human leptin receptor gene that results in a truncated leptin receptor lacking both the transmembrane and the intracellular domains. In addition to their early-onset morbid obesity, patients homozygous for this mutation have no pubertal development and their secretion of growth hormone and thyrotropin is reduced. These results indicate that leptin is an important physiological regulator of several endocrine functions in humans.


Subject(s)
Carrier Proteins/genetics , Mutation , Obesity/genetics , Pituitary Diseases/genetics , Receptors, Cell Surface , Adult , Body Height , Body Weight , Carrier Proteins/physiology , Family Health , Female , Genotype , Homozygote , Human Growth Hormone/metabolism , Humans , Male , Pituitary Diseases/physiopathology , Polymorphism, Single-Stranded Conformational , RNA, Messenger/metabolism , Receptors, Leptin
19.
FEBS Lett ; 415(2): 217-20, 1997 Sep 29.
Article in English | MEDLINE | ID: mdl-9350999

ABSTRACT

Apolipoproteins A-II and C-III, which participate in the control of cholesterolemia and triglyceridemia, are negative acute phase proteins. Treatment of HepG2 cells with TNFalpha showed that apoA-II and apoC-III mRNA levels were decreased. Using transient transfection, we found that apoC-III gene expression is controlled at the transcriptional level. By competition and supershift experiments, we demonstrate that TNFalpha-induced complexes were related to C/EBPdelta/NF-IL6beta and p50 and that overexpression of C/EBPdelta was able to reproduce the inhibitory effect of TNFalpha on the apoC-III promoter. RT-PCR failed to detect the IL-1 transcript in TNFalpha-treated HepG2 cells, suggesting that activation of C/EBPdelta by TNFalpha is not related to the IL-1-signalling pathway.


Subject(s)
Apolipoproteins C/genetics , CCAAT-Enhancer-Binding Proteins , DNA-Binding Proteins/metabolism , Gene Expression Regulation, Neoplastic , Interleukin-1/metabolism , Nuclear Proteins/metabolism , Transcription Factors/metabolism , Tumor Necrosis Factor-alpha/pharmacology , Apolipoprotein A-II/genetics , Apolipoprotein A-II/metabolism , Apolipoprotein C-III , Apolipoproteins C/metabolism , CCAAT-Enhancer-Binding Protein-delta , Carcinoma, Hepatocellular , Chloramphenicol O-Acetyltransferase/genetics , Chloramphenicol O-Acetyltransferase/metabolism , DNA-Binding Proteins/genetics , Humans , NF-kappa B/genetics , NF-kappa B/metabolism , NF-kappa B p50 Subunit , Nuclear Proteins/genetics , RNA, Messenger/genetics , RNA, Messenger/metabolism , Transcription Factors/genetics , Transcription, Genetic , Transfection , Tumor Cells, Cultured
20.
Exp Cell Res ; 236(1): 311-20, 1997 Oct 10.
Article in English | MEDLINE | ID: mdl-9344612

ABSTRACT

The culture of Caco-2 cells on plastic support impairs the expression of several genes involved in lipid metabolism. We describe culture conditions that permit the expression of the I-FABP gene and better expression of the apolipoprotein A-I, C-III, and A-IV genes. Basal lamina deposited on filters as well as the nature of nutrients on the apical side differentially modulated mRNA expression of I-FABP, APOBEC-1, and apolipoprotein genes. Growing cells on a filter led to functional polarization, illustrated by a secretion of apo B at the basal side, which induced the expression of the I-FABP, APOBEC-1, and apo A-IV genes and highly increased the expression of the apo C-III gene. Moreover, basal lamina deposited on the filter enhances the mRNA expression of apo A-I. Apo C-III and A-IV mRNA levels were decreased when cells were grown on a filter covered with basal lamina in the presence of a medium deprived of protein and lipid on the apical side, whereas these conditions had no effect on I-FABP, apo A-I, and APOBEC-1 mRNA levels. The addition of lipid micelles on the apical side had various effects, according to the genes. Caco-2 cells cultured under the conditions described here closely resembled enterocytes and represent a useful tool for studying the regulation of genes involved in lipid metabolism.


Subject(s)
Apolipoproteins/genetics , Caco-2 Cells/cytology , Carrier Proteins/genetics , Myelin P2 Protein/genetics , Neoplasm Proteins , Tumor Suppressor Proteins , APOBEC-1 Deaminase , Basement Membrane/physiology , Blood Proteins/pharmacology , Caco-2 Cells/metabolism , Caco-2 Cells/ultrastructure , Cell Differentiation/drug effects , Cell Differentiation/physiology , Cytidine Deaminase/genetics , Fatty Acid-Binding Protein 7 , Fatty Acid-Binding Proteins , Fatty Acids/genetics , Fluorescent Antibody Technique , Gene Expression Regulation, Neoplastic/drug effects , Gene Expression Regulation, Neoplastic/physiology , Humans , Lipids/pharmacology , Micelles , Microscopy, Electron , RNA Processing, Post-Transcriptional/genetics , RNA, Messenger/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...